

**BIO TECHNOLOGY LAW GROUP**  
PATENT, TRADEMARK & COPYRIGHT ATTORNEYS  
527 N. Highway 101, Suite E

Telephone 858 350 9690

Facsimile 858 350-9691

**RECEIVED**  
**CENTRAL FAX CENTER**

**JUL 26 2007**

## **Fax Transmission**

**To:** Mail Stop M Correspondence  
**Company:** United States Patent & Trademark Office  
**Fax #:** 571-273-8300

**From:** Daniel M. Chambers  
**Date:** July 26, 2007  
**Re:** Docket # GTI-5000-CT3

**You should receive 3 page(s) including this one.**  
**If you do not receive all pages, please call 858 350 9690.**

**Genetronics, Inc.: GTI-5000-CT3**

**Matter:** Method for Muscle Delivery of Drugs, Nucleic Acids and Other Compounds

Dear Sir/Madam:

I respectfully submit via facsimile transmission the cover sheet and a letter to claim Small Entity status for the above-identified patent. Your prompt attention to implement this change is requested.  
Thank you in advance for your assistance.

Should you have any questions, please do not hesitate to contact me.

Sincerely,

Daniel M. Chambers (Reg. No.: 34,561)  
BioTechnology Law Group

**This transmission contains information that is confidential and/or legally privileged. It is intended for use only by the person to whom it is directed. If you have received this facsimile in error, please notify us by telephone immediately so that we can arrange for the return of the original documents to us. If you do NOT receive all of the pages, please telephone us in the U.S.A. at 858 350 9690 or FAX us at 858 350-9691.**

**BIOTECHNOLOGY LAW GROUP**

527 N. HIGHWAY 101, SUITE E  
SOLANA BEACH, CA 92075-1173

DANIEL M. CHAMBERS, A. P. C.  
TEL: (858) 350-9690 FAX: (858) 350-9691  
EMAIL: dan@biotechnologylawgroup.com

RECEIVED  
CENTRAL FAX CENTER

JUL 26 2007

July 26, 2007

Mail Stop M Correspondence  
Director of the US Patent and Trademark Office  
PO Box 1450  
Alexandria, VA 22313-1450

Re: USA Application 10/115,230, Patent 6,800,484;  
BLG Ref: GTI-1120-DV

Re: USA Application 09/090,471, Patent 6,027,488;  
BLG Ref: GTI-1220-UT

Re: USA Application 09/307,216, Patent 6,347,247;  
BLG Ref: GTI-1230-UT

Re: USA Application 10/339,708, Patent 7,171,264;  
BLG Ref: GTI-1360-CP

Re: USA Application 10/215,963, Patent 7,054,685;  
BLG Ref: GTI-1370-DV

Re: USA Application 07/929,103, Patent 5,273,525;  
BLG Ref: GTI-1500-UT

Re: USA Application 09/176,136, Patent 6,150,148;  
BLG Ref: GTI-1560-UT

Re: USA Application 08/729,007, Patent 5,704,908;  
BLG Ref: GTI-1580-UT

Re: USA Application 09/874,468, Patent 6,748,265;  
BLG Ref: GTI-1590-UT2

Re: USA Application 10/620,271, Patent 6,958,060;  
BLG Ref: GTI-5000-CT3

Mail Stop M Correspondence  
Director of the US Patent and Trademark Office  
July 26, 2007  
Page 2

RECEIVED  
CENTRAL FAX CENTER  
JUL 26 2007

Please note that the referenced patents qualify as a small entity. If you have any questions please do not hesitate to contact me.

Sincerely,



Daniel M. Chambers  
Daniel M. Chambers, A.P.C.  
BioTechnology Law Group

DMC:dg